Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Debt (2020 - 2021)

Insight Molecular Diagnostics (IMDX) has disclosed Non-Current Debt for 2 consecutive years, with $178000.0 as the latest value for Q3 2021.

  • Quarterly Non-Current Debt fell 91.38% to $178000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $178000.0 through Sep 2021, down 91.38% year-over-year, with the annual reading at $1.5 million for FY2020, N/A changed from the prior year.
  • Non-Current Debt hit $178000.0 in Q3 2021 for Insight Molecular Diagnostics, down from $541000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $2.6 million in Q2 2020 to a low of $178000.0 in Q3 2021.